A new study was approached by Martin Friedlander and colleagues, at the Scripps Institute, La Jolla, suggesting a simpler way to reduce VEGF induced blood vessel in the eye which causes vision loss.
In most disease, vision loss is caused, when the permeability of blood vessels in the retina of eye is alerted by other factors (e.g, fluid accumulating in the retina impairing eyesight). Molecule VEGF is a initiator of increased blood vessel permeability. If VEGF antagonists stabilizes, the eyesight of some patients can be improved. But this treatment requires repeated injection of the VEGF antagonist into the eye which is a painful procedure.
Martin Friedlander and colleagues found a small molecule inhibitor of signaling molecules that associate with the receptors of VEGF (known as Src kinases). This molecule can eliminate VEGF induced accumulation of fluid in the retina of mice and rabbits. The effect was observed when the inhibitor was both injected intravenously and used as an eye drop.
Now, they are trying to use this approach to benefit individuals who are suffering from many disease which are caused due to vision loss through VEGF-induced increased blood vessel permeability.
Source: Look to the future: New drug reduces one cause of vision loss
Filed under Dry Eyes, Eye Diseases, Eye Treatment, Improved Vision | Tags: eye, Src kinases, the Scripps Institute, VEGF | Comment Below
Related?
Lasik corrects eyesight for 2003 Wildfire Victim Rudy ReyesSeptember 16th, 2005 Rudy Reyes, 28, has been through 27 surgeries since he was badly burned in the October 2003 wildfires, so he was a little nervous about undergoing a procedure to correct his eyesight. He was legally blind without glasses according to ophthalmologist Richard Leung.
Midwest Eye Institute Doctor Helps To Test Drug For Macular Degeneration June 8th, 2008 The Macular degeneration is the type of eye disease that develops in the older people. It is one of the major causes of vision loss in countries like the USA, especially among the age group of 65 and above.
Eye Drug Lucentis Recommended by UK's NICE to Treat Wet AMDJune 14th, 2007 Novartis AG's Lucentis drug against wet age-related macular degeneration (AMD) received a recommendation from the UK's National Institute for Health and Clinical Excellence (NICE) for use on the National Health Service. Lucentis should be used for about 20 pct of patients with AMD, a condition which causes sight loss and blindness, when both eyes are affected, NICE said in a statement last night.
Statin can lead to eye disease December 2nd, 2008 The American Academy of Ophthalmology, found that the cholesterol lowering drug Statin can cause eye disorders. The drug Statin helps prevent coronary heart disease, stroke and other deaths related to high cholesterol levels.
Corneal neovascularization (Blood Vessels Growth) could be treated by AvastinApril 16th, 2009 New study confirms that short-term topical bevacizumab therapy reduces the severity of formation of new blood vessels in the cornea that can create impaired vision or vision loss. The results are currently published online on the Archives of Ophthalmology website at www.archophthalmol.com.
Most expensive drug "Lucentis" now available through cost effective scheme by NICE August 27th, 2008 National Institute For Clinical Excellence (NICE) has launched a special scheme which will help people suffering from macular degeneration to avail Novartis AG's, pricey eye drug Lucentis through cost effective scheme. This move, follows a draft plan in which the National Health Service will pay for a maximum of 14 injections of Lucentis per eye, with Novartis agreeing to pay if any more are needed.
Now, drug-delivering contact lensesJuly 22nd, 2009 WASHINGTON - Glaucoma patients and dry-eye sufferers may soon be able to trade their messy eye drops for a contact lens that delivers medication gradually over time, say scientists. Medication through eye drops tends to be highly ineffective, not because the drugs are impotent, but because of the body's own natural defences.
Antibiotic Fights Lymphoma of Eye Linked to ChlamydiaOctober 4th, 2006 The antibiotic doxycycline is proving an effective treatment for a lymphoma of the eye linked to chlamydia infection, Italian researchers report. This cancer of the eyelids and related tissues is called "ocular adnexal lymphoma of the MALT-type" (OAL).
